Opus Genetics Advances 5 IRD Clinical Programs; Funded into 2029
Opus Genetics, Inc. presented at its Virtual R&D Science Forum, highlighting its robust pipeline and clinical development strategy for inherited retinal diseases (IRDs). The company announced it is fully-funded to advance five IRD clinical programs, with a cash runway extending into 2029. Key milestones include planned clinical study initiations for RDH12, MERTK, and RHO programs, as well as Phase 3 dosing for LCA5 and initial results for BEST1. The presentation also shared positive efficacy and durability data for OPGx-LCA5, including significant participant-reported improvements.
Key Highlights
- Opus Genetics is fully-funded to advance 5 inherited retinal disease (IRD) clinical programs.
- Current cash runway extends into 2029, funding programs through potential product approvals.
- Initiation of RDH12 clinical study is targeted for Q4 2026 in the U.S.
- Initiation of MERTK clinical study is targeted for Q1 2027 in Abu Dhabi.
- Initiation of RHO clinical study is targeted for 2H 2027 in global locations.
- LCA5 Phase 3 dosing initiation is targeted for Q4 2026.
- BEST1 Cohort 1 3-month results are expected in September 2026.
- OPGx-LCA5 demonstrated durable vision improvement in adults over 24 months and in pediatric patients over 6 months.
Price Impact
More from IRD
Opus Genetics Presents Positive Clinical Data for OPGx-BEST1 and OPGx-LCA5 Gene Therapies
Opus Genetics Reports Q2 Net Loss of $73.6M; Equity Turns Negative
Opus Genetics Q2 Net Loss $8.1M; OPGx-BEST1 Data Sept 2026; Cash to 2029
More in Clinical Trial